Why Medical Developments International Ltd's share price is up 14% this week

The shares of Medical Developments International Ltd (ASX:MVP) have rocketed this week. Is it too late to invest in this explosive healthcare company?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a great start to the new year for the shareholders of Medical Developments International Ltd (ASX: MVP).

The growing healthcare company behind the popular green whistle pain management device has seen its share price rocket 14% this week despite there being no news out of the company.

This week's gain is likely to be attributable to a buy recommendation placed on its shares at the weekend by Patersons Securities as reported in the News Corp media.

I can't say I'm surprised to see the company finding favour with brokers, especially with its shares around 23% off their 52-week high.

I see this as a great price to start a long-term buy and hold investment in a company with enormous growth potential.

In 2016 MDI gained approval for its Penthrox product in countless countries as part of the company's plan to make it the mainstream analgesic of choice around the world.

This looks set to continue in 2017 with the company expected to gain approval for its sale in more than 20 countries throughout Europe. Furthermore, MDI is gathering the clinical data needed to submit a new drug application to the U.S. Food & Drug Administration.

If that wasn't enough, management recently revealed that it has embarked on a clinical program to expand its use into minor surgical procedures. This is a potentially lucrative expansion with this particular market estimated to be worth upwards of $2 billion a year to the company.

As well as Penthrox the company has another weapon in its arsenal. It was recently granted FDA approval for its anti-static space chamber devices used to help patients manage their asthma and chronic obstructive pulmonary disease.

With management confident both products beat the current competition on quality and price, I believe 2017 could be a year of significant growth.

But with its shares changing hands at 117x trailing earnings, an investment in its shares does carry significant risk. Whilst I believe that its growth potential means it is worth the premium, I would suggest restricting any investment to just a very small part of your portfolio.

If it is a little too expensive for your tastes then I would point you to CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX). Both companies also have solid growth prospects, but come at more reasonable valuations.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »